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INTRODUCTION
A good functioning AV fistula or graft is directly linked
to improved quality of life of patients on hemodialysis.
Access problems are common and frequent reason of
hospitalisation for these patients.1 The most common
issues of hemodialysis accesses are poor flow, throm-
bosis, bleeding or inadequate dialysis due to central
venous stenosis (CVS). 
About 11% to 40% of the patients on hemodialysis have
CVS.2 Patients with previous history of central line
placement and having AV access on the ipsilateral arm
are at risk of developing CVS.3 Patients may present
with severe arm, neck, and breast oedema.4 They also
have malfunctioning accesses with inadequate dialysis. 
Over the last two decades, percutaneous methods have
taken over the surgery for treatment of CVS5 due to their
minimal invasiveness. They are considered to be
effective in improving the patency of failing AV accesses,6
and also relieving patient's symptoms. There is little
reported in loco-regional literature on the outcomes of
these procedures.7
The objective of this study was to determine the success
of percutaneous venoplasty in terms of relieving symp-
toms of CVS and improving the patency of AV accesses.
METHODOLOGY
This was a retrospective study conducted at the Aga
Khan University Hospital from January 2012 to December
2017. All patients, who had CVS in upper arm or lower
leg, were included in the study. 
Patients who were lost to follow-up or had incomplete
records were excluded from the study. Data about patients’
demographics, symptoms, existing co-morbidities, indi-
cation for CVS intervention, and location of lesion were
retrieved and recorded on specially designed proforma. 
All patients had standard percutaneous venoplasties
with plain balloons. Technical success was considered when
there was less than 30% residual stenosis. Stenting was
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considered in patients when residual stenosis of more
than 50%, with elastic recoil or with complication.
Patients were monitored for any post-procedure compli-
cations such as bleeding, access site hematoma or
access thrombosis. Patients were allowed to use
accesses soon after the procedure, if needed. Patients
were followed in vascular surgery clinics at 3-month
interval.
The outcomes measured were symptomatic recovery
and improvement in the patency of arteriovenous access.
Symptomatic recovery was termed 'complete', when
there was complete symptomatic relief after venoplasty;
and 'partial' when the procedure was technically
successful but symptoms that led to venoplasty, were
not resolved.
Patency of AV accesses were measured as primary and
cumulative patency. Primary patency was the duration of
time from first intervention to next intervention or fistula
failure. Cumulative patency was the total duration of time
fistula remain, patent with multiple interventions.
Events considered end points to functional access status
were placement of new access site, ligation of access
site, dialysis catheter placement or the patient death.
Categorical variables were reported as frequencies
along with their percentages. Continuous variables were
reported as mean ± standard deviation. Patency rate
was calculated using Kaplan-Meier survival curve. A
p-value of <0.05 was considered as significant. Analyses
were performed using SPSS version 22 (IBM Inc.).
RESULTS
During the study period, 48 patients had attempted
venoplasty. Thirteen patients were excluded as wire was
not negotiable through the lesion. Thirty-five patients
had technically successful venoplasty. The mean age
of the patients was 56.86 ±14.6 years. Most of them
were females (21, 60%). The major comorbidities
were hypertension and diabetes (Table I). Twenty-four
(68.6%) patients had native arteriovenous fistula, while
11 (31.4%) had arteriovenous grafts.  
Twenty-three (65.7%) patients presented with arm swelling,
10 (28.6%) patients with poor flow, and 2 (5.7%) patients
with increased pressure during dialysis. 
The most common sites of stenosis were brachio-
cephalic vein followed by subclavian vein. One patient
had balloon leak, while another patient had cardiac
event in post-procedure day, which settled with medical
management.
Twenty-one (60%) patients had initial complete relief
of symptoms and 14 (40%) patients had partial relief.
Primary patency was 40%, 24%, 24% at 6, 12 and 24
months. Cumulative patency was 69%, 66% and 59% at
6, 12 and 24 months (Figures 1 and 2).
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Table I: Demographics of patients and details of arteriovenous accesses.
N=35 Number (%)
Comorbidities
Hypertension 34 (97.1)
Diabetes mellitus 16 (45.7)
Coronary artery disease 8(22.9)
Hepatitis C 5(14.3)
Polycystic kidney disease 2(5.7)
Hypothyroidism 3(8.6)
Systemic lupus erythrosclerosis 3(8.6)
Site of fistula
Left arm 24 (68.6)
Right arm 9 (25.7)
Left leg 1 (2.9)
Right leg 1 (2.9)
Site of stenosis
Axillary vein 8 (22.9)
Subclavian vein 9 (25.7)
Brachiocephalic vein 16 (45.7)
External Iliac vein 1 (2.9)
Common Iliac vein 1 (2.9)
Figure 1: Graph showing primary patency of arteriovenous accesses.
Figure 2: Graph showing cumulative patency of arteriovenous accesses.
Twenty-six (74%) patients had recurrence of symptoms.
Twenty-one (60%) patients underwent repeat angioplasty.
Five patients (14%) had surgical management for CVS.
Ligation and formation of new AVF in one patient; two
patients had thrombectomies, while two patients had
bypass procedures for relieving CVS. Four patients had
stents placed. One stent was placed at the time of first
angioplasty and three were placed at the time of the
repeated venoplasty sessions.
DISCUSSION
The present study showed that CVS venoplasty improved
patients’ symptoms and also improved the short term
patency of vascular access. Seventy-four percent
patients had recurrence in which most patients required
repeated venoplasty. There were no major complication
encountered. All accesses were usable for dialysis soon
after the procedure.
Bakken et al. showed improved haemodialysis access
patency of 77%, 73% and 57% at 3, 12 and 24 months
after CVS venoplasty.8 Bountouris et al. also noted
patency of 42% at 24 months.9 Glanz S et al. noted
1-year patency rate of 35%.10 The results are consistent
with this study. Ya et al. showed, PTA for CVC achieved
technical success in 92% of cases, and symptoms were
initially alleviated in 96% of subjects.11 Others have also
documented the efficiency of this modality.12 The authors
also found it effective in relieving patients arm swelling.
Many authors have highlighted the issue of recurrence
after initial venoplasty and considered it a norm. Ya et al.
showed recurrence rate of 58% at 4 months after PTA.11
Same were the findings of the Sprouse et al. and
Argarwal et al.13,14 Inflating the balloon itself caused
local intimal injury and may induce neointimal hyper-
plasia, hence recurrent venous stenosis.
Plain balloons were used but better patency may be
achievable with cutting balloons,15 drug-eluting balloons,16
or specialised high pressure balloons. These were
neither available nor feasible due to higher cost. 
The use of stents is controversial during intervention.
Many of the previous studies fail to demonstrate whether
stenting provides additional benefit or not. Stents were
offered only to those patients who had elastic recoil or
had significant persistent stenosis. There have been
studies which document better patency rates following
stenting. However, long term patency is not seen in all
cases. Quinn et al. compared stenting with PTA alone
and saw that patency rates were comparative in both
cases.17 Oderich et al. reported that primary patency
remains same at one year and re-intervention rate is not
better than the presently reported results.18
The limitations of this study include being a retrospective,
collection of data from a single institute with limited
number of patients. Despite this, it showed the efficiency
of PTA in relieving arm oedema and improving short
term longevity of AV accesses.
CONCLUSION
Percutaneous venoplasty for CVS can provide symp-
tomatic relief in majority of the patients and can improve
the short term patency of arteriovenous access.
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